-
Represented National Securities Corporation, as the sole book-running manager, and ROTH Capital Partners and Craig-Hallum Capital Group, as co-managers, in an initial public offering by Restoration Robotics, Inc. (Nasdaq: HAIR) of approximately $25 million of its common stock.
-
Represented DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) in connection with a $10 million registered direct offering.
-
Represented Laidlaw & Company (UK) Ltd., as placement agent, in connection with a registered direct offering for MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX)
-
Represented Oppenheimer & Co. Inc., as sole underwriter, in connection with a public offering for VistaGen Therapeutics, Inc. (Nasdaq: VTGN).
-
Represented Cancer Genetics Inc. (Nasdaq: CGIX) in its $16 million registered direct offering of common stock to Aspire Capital Fund LLC.
-
Represented Aegis Capital Corp., as placement agent, in connection with a $3.2 million registered direct offering and concurrent private placement of xG Technology, Inc. (Nasdaq: XGTI).
-
Represented Ladenburg Thalmann & Co. Inc., as exclusive underwriter, in connection with a $11.5 million public offering of MicroVision, Inc. (Nasdaq: MVIS).
-
Represented Oppenheimer & Co. Inc., as underwriter, in a $16.125 million underwritten public offering of Actinium Pharmaceuticals, Inc. (NYSEMKT: ATNM).
-
Represented Oppenheimer & Co. Inc, as sales agent, in connection with an $8.4 million at-the-market offering for OncoSec Medical Incorporated (Nasdaq: ONCS).
-
Represented ROTH Capital Partners, LLC, as exclusive underwriter, in connection with a public offering for EnSync, Inc., dba EnSync Energy Systems (NYSEMKT: ESNC).
-
Represented Rodman & Renshaw, a unit of H.C. Wainwright & Co., as the exclusive placement agent, in connection with a $10 million public offering for EyeGate Pharmaceuticals, Inc. (Nasdaq: EYEG).
-
Represented DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) in connection with a $9 million public offering.
-
Represented Laidlaw & Co., as placement agent, in connection with a $7 million private placement for Cooltech Holding Corp.
-
Represented Matinas BioPharma Holdings, Inc. (NYSEMKT: MTNB) in connection with its $30 million at-the-market offering.
-
Represented Maxim Merchant Capital, a division of Maxim Group LLC, as sole placement agent, in connection with a private offering for Virtual Health Partners, Inc.
-
Represented Provention Bio, Inc. in connection with a $28.4 million private placement.
-
Represented Maxim Merchant Capital, a division of Maxim Group LLC, as sole placement agent, in connection with a $25 million private offering for Diffusion Pharmaceuticals, Inc. (Nasdaq: DFFN).
-
Represented Special Situations Funds, as lead investor, in connection with a $15 million private placement in Ideal Power Inc.
-
Represented Presbia PLC (Nasdaq: LENS) in connection with a $10.8 million rights offering.
-
Represented Arch Therapeutics, Inc. (OTCQB: ARTH) in a $6.1 million registered direct offering.
-
Represented Aytu BioScience, Inc. (OTCQX: AYTU) in a warrant tender offer.
-
Represented CytoDyn Inc. (OTCQB: CYDY) in a registered direct offering.
-
Represented Motus GI Holdings, Inc., in connection with its $30 million private placement.
-
Represented Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) in connection with a $27.2 million registered direct offering.
-
Represented Aegis Capital Corp., as sole underwriter, in connection with a public offering for xG Technology, Inc. (Nasdaq: XGTI).
-
Represented Matinas BioPharma Holdings, Inc. (NYSEMKT: MTNB) in connection with a $13.5 million warrant tender offer.
-
Represented Malvern Bancorp, Inc. in its private placement of $25 million in aggregate principal amount of fixed-to-floating rate subordinated notes to certain institutional investors.
-
Represented Lakeland Bancorp, Inc. in its public offering of $75 million in aggregate principal amount of fixed-to-floating rate subordinated notes.
-
Represented Lakeland Bancorp, Inc. in the sale of $50 million of its common stock through an at-the-market equity offering.
-
Represented Oppenheimer & Co. Inc. which acted as the representative for the initial purchasers in Akoustis Technologies, Inc.’s (NASDAQ: AKTS) Rule 144A offering of 6.5% Convertible Senior Secured Notes.
-
Centivo, a new type of self-funded health plan, in its $34 million Series A financing led by Bain Capital Ventures, with additional investments from F-Prime Capital Partners, Maverick Ventures, Bessemer Venture Partners, Ingleside Investors, Rand Capital, Grand Central Tech Ventures, and Oxeon Investments.
-
Perch, the marketplace for buying and selling homes, in its $30 million Series A financing led by FirstMark Capital, with Juxtapose and Accomplice also participating in the round.
-
Aetion, Inc. in its $36.4 million Series B financing, in a round led by New Enterprise Associates (NEA) and including, as a new investor, Amgen Ventures, alongside existing investors Flare Capital Partners, Lakestar, and Oxeon Ventures. We previously represented Aetion in is $11.2 million Series A financing led by Flare Capital Partners and joined by Lakestar.
